Found 83 Menstruation trials
A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This trial evaluates the effect of continuing treatment with caffeine citrate in the hospital and at home in moderately preterm infants with resolved apnea of prematurity on days of hospitalization after randomization. It is a randomized, double-blinded, placebo-controlled, multicenter trial. The primary outcome of the study will be the number …
The Women's Health Clinical Research Center at University of Pennsylvania is currently recruiting healthy women who have regular periods and do not wish to become pregnant for at least 12 months for a research study of an investigational birth control patch. The study patch that will be used in this …
A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …
This is a dose range finding safety study of Branaplam administered as weekly oral doses in participants with early manifest HD. The study aims to explore a range of doses to select a safe and tolerable dose that lowers mutant huntingtin protein (mHTT) levels in the CSF to a degree …
This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD. Study details include: Study duration: Screening - up to 4 weeks; Primary Analysis Period (PAP) - 52 weeks; Extended Treatment Period …
This is a multicenter, exploratory, open-label study to explore the efficacy and/or pharmacodynamic effect, PK, safety, and tolerability of mavacamten in approximately 35 ambulatory participants with symptomatic HFpEF and elevated cTnI and/or elevated NT-proBNP as defined in inclusion/exclusion criteria. The study will include an up to 7-week screening period (with …
This study is being done to test the safety, effectiveness, and side effects of 2 different doses of the study drug, BI 1015550, when compared to taking a placebo, in subjects with PF-ILD. In this study you will either get the active study drug, BI 1015550 or a placebo. If …
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects. Two dose levels of PDA-002 (3 x 106 and 30 x 106 cells) versus placebo will be evaluated in 1:1:1 randomization approach. Subjects will …
The purpose of this study is to see if the study drug ABBV-154 is safe and able to treat subjects with moderately to severely active Crohn's Disease who have an inadequate response to or were intolerant of prior biologics. ABBV-154 is an antibody-drug conjugate, which means it is composed of …
Please choose between Voice or SMS based delivery of verification code
or